Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced its business update and financial results for the first nine months of 2025. "This quarter highlights ...
Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA®– Q3 2025 operating profit of €11.0 million– TransCon® ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈